AgingResearch.NewsJoin free

Zoledronate

Zoledronate has been studied in 5 papers since 2021: 2 trials in people, 2 in animals; 1 in the past year. The newest paper, Mar 25, 2026: “Treadmill Exercise Enhances the Effects of Zoledronate on Bone Microarchitecture and Mechanical Strength in Ovariectomized Rat Model of Osteoporosis”.

Intervention

5 papers study it93 more mention it7 findingsUpdated

PubChemChEBI

7 new papers in 30 daysSee all 98

“The evolution of the zoledronate effects on BMD were almost identical whether or not women were using NSAIDs at baseline and were significant in both subgroups at all BMD sites (p < 0.0001).”
No Effect of NSAID Use on Efficacy of Zoledronate: A Post Hoc Analysis of a Randomized Trial in Osteopenic Older WomenJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2023doi:10.1002/jbmr.4887

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

About aging: trials about aging, of every trial that tests the drug for any use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

  • 2 independent labs in 2 countries
  • 41 trials, 1 about aging, 24 with no results posted
  • Funders: Academy of Medical Sciences and 4 more
  • 40 of 41 trials sponsored by its developers
  • Human trial2
  • Animals1
  • Model organisms1
  • In silico1

Studies in people

2 studies gave zoledronate to people and measured what changed.

  • up: Increases bone density

    down: Lowers the risk of fracture

    Randomized trial2,000 peopleWomen6-year

    Older adults; Postmenopausal women; whether or not women were using NSAIDs at baseline

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Jul 21, 2023

  • down: Decreases height lossp = 0.0001

    Randomized trial2,000 peopleWomen>65 years6 years

    Older adults; Postmenopausal women; osteopenic

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Sep 3, 2022

What did studies of Zoledronate find?

5

Studies of Zoledronate measured 5 outcomes; the most studied are bone density (1 study), height loss (1) and intestinal epithelial dysplasia (1).

Bone density

upin humans1

1 study

  1. Zoledronate increases bone density in humans.

    “The evolution of the zoledronate effects on BMD were almost identical whether or not women were using NSAIDs at baseline and were significant in both subgroups at all BMD sites (p < 0.0001).”

    Human trialwhether or not women were using NSAIDs at baseline6-yearfemalesn = 2,000

    No Effect of NSAID Use on Efficacy of Zoledronate: A Post Hoc Analysis of a Randomized Trial in Osteopenic Older Women

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Height loss

downin humans1

1 study

  1. Zoledronate decreases height loss in humans (p = 0.0001).

    “Multivariate analysis of baseline predictors of height change showed that age accelerated height loss (p < 0.0001) and zoledronate reduced it (p = 0.0001).”

    Human trialosteopenic6 yearsfemalesn = 2,000

    Zoledronate Reduces Height Loss Independently of Vertebral Fracture Occurrence in a Randomized Trial in Osteopenic Older Women

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Intestinal epithelial dysplasia

downin flies1

1 study

  1. Zoledronate decreases intestinal epithelial dysplasia in flies.

    “reduced intestinal epithelial dysplasia and permeability with age”

    Model organisms

    Zoledronate Extends Health Span and Survival via the Mevalonate Pathway in a FOXO-dependent Manner

    The journals of gerontology. Series A, Biological sciences and medical sciences

Climbing activity

upin flies1

1 study

  1. Zoledronate improves climbing activity in flies.

    “improved climbing activity”

    Model organisms

    Zoledronate Extends Health Span and Survival via the Mevalonate Pathway in a FOXO-dependent Manner

    The journals of gerontology. Series A, Biological sciences and medical sciences

Lifespan

upin flies1

1 study

  1. Zoledronate extends lifespan in flies.

    “Zol extended life span”

    Model organisms

    Zoledronate Extends Health Span and Survival via the Mevalonate Pathway in a FOXO-dependent Manner

    The journals of gerontology. Series A, Biological sciences and medical sciences

What is Zoledronate linked with?

1

Studies link Zoledronate with 1 measure, most often fracture (1 study).

Fracture

downin humans1

1 study

  1. Zoledronate lowers the risk of fracture in humans.

    “The odds of fracture were significantly reduced in both NSAID users and nonusers.”

    Human trialin both NSAID users and nonusers6-yearfemalesn = 2,000

    No Effect of NSAID Use on Efficacy of Zoledronate: A Post Hoc Analysis of a Randomized Trial in Osteopenic Older Women

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

What acts on Zoledronate?

1

Studies name 1 thing that act on Zoledronate, most often foxo (1 study).

foxo

is required forin flies1

1 study

  1. foxo is required for zoledronate in flies.

    “required dFOXO for its action”

    Model organismsfor zoledronate action

    Zoledronate Extends Health Span and Survival via the Mevalonate Pathway in a FOXO-dependent Manner

    The journals of gerontology. Series A, Biological sciences and medical sciences

More on foxo

Has Zoledronate been tested in people?

1 about aging, of 41

Yes: 2 trials in people have been published.

About aging

Latest

Nov 2025: 1Dec 2025: 0Jan 2026: 3Feb 2026: 2Mar 2026: 2Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 1Aug 2026: 3Sep 2026: 3Oct 2026: 420 papers in 12 months
Journal of Cachexia, Sarcopenia and Muscle

Denosumab linked to greater grip strength gains in women

At 12 months, grip strength rose 1.45 kg with denosumab versus 0.66 kg with zoledronic acid in postmenopausal women with osteoporosis.At 12 months, grip strength rose 1.45 kg with denosumab versus 0.66 kg with zoledronic acid in postmenopausal women with osteoporosis.

Cohort · 186 peopleDenosumab
Paper

See all 98

Related